市場概況

The Nucleic Acid Based Therapeutics Market is poised for significant growth, with a projected expansion from USD 4.28 億で 2022 米ドルへ 9.51 10億まで 2029, reflecting a robust compound annual growth rate (CAGR) の 11.6% の予測期間中に 2023-2029. This market primarily revolves around the development and utilization of nucleic acid therapeutics for the treatment of various diseases. Notable examples of nucleic acid-based therapeutics include aptamers, antisense oligonucleotides (ASOs), and small interfering RNAs (siRNAs), which are designed to specifically target and suppress disease-related genes. ASOs and siRNAs, 特に, have demonstrated their efficacy in silencing genes by interfering with mRNA translation and nuclear DNA transcription.

The demand for nucleic acid-based therapeutics has witnessed a significant surge, driven by their successful application in the treatment of COVID-19. Research has shown promising results in utilizing these therapeutics to suppress viral gene expression, offering potential avenues for combating viral infections. 世界的に, there are currently over 400 RNA-targeting drug development projects underway, indicating a strong growth trajectory for the market throughout the forecast period.

The increasing prevalence of genetic diseases necessitates the development of innovative treatment approaches, and nucleic acid-based therapeutics offer a promising solution by targeting and correcting abnormal gene expression. さらに, investments in healthcare infrastructure and research and development activities, along with collaborations between pharmaceutical companies and academic institutions, further drive market growth. The pharmaceutical industry’s focus on developing innovative biologics, including nucleic acid-based therapeutics, also contributes to the expansion of the market.

市場セグメンテーション

市場は、製品タイプに基づいてセグメント化されています, 応用, エンドユーザー, そして地理.

製品タイプ別のセグメンテーション
RNA interference (RNAi) and short interfering RNAs (siRNAs)
Antisense Oligonucleotides (ASOs)
その他

アプリケーションによるセグメンテーション
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
その他

エンドユーザーごとのセグメンテーション
Hospitals and Clinics
Academic and Research Institutes

地理によるセグメンテーション
北米 – アメリカ, カナダ, メキシコ
ヨーロッパ – イギリス, ドイツ, フランス, イタリア, スペイン, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, インド, オーストラリア, 韓国, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, アルゼンチン, およびその他のラテンアメリカ諸国
中東とアフリカ – GCC, 南アフリカ, およびその他の中東およびアフリカ

Antisense oligonucleotides (ASOs) selectively bind to specific mRNA sequences, degrading or inhibiting their translation into protein. ASOs show promise for treating genetic disorders, 感染症, and cancer. Approved ASO therapies like Spinraza, Exondys51, Onpattro, and Tegsedi demonstrate this approach’s success. The ASOs segment is expected to grow due to increased demand, R&D activities, and new product introductions. Business strategies like partnerships and acquisitions drive growth, resulting in the availability of more ASO products and increased company activities.

North America is expected to hold a significant market share due to growing research on nucleic acid-based therapies, increasing prevalence of genetic and chronic disorders, and rising investments in research and development. The demand for nucleic acid-based therapies is driven by the prevalence of autoimmune diseases and the burden of cancer. Market growth is further supported by innovative product launches, approvals, partnerships, 買収, expansions, and collaborations in the region.

競争環境

The nucleic acid-based therapeutics market is moderately fragmented, with numerous global and regional players actively researching and developing therapeutics for chronic, genetic, および感染症. Notable participants include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Moderna Inc., ノバルティスAG, Sarepta Therapeutics Inc., Silence Therapeutics PLC, Stoke Therapeutics Inc., and Wave Life Sciences Ltd.

最近の業界の発展

3月に 2023, Ionis Pharmaceuticals received FDA approval for potential accelerated approval of Tofersen for SOD1-ALS treatment. Tofersen reduces SOD1 protein synthesis.

2月中 2023, Myeloid Therapeutics Inc. collaborated with the NSW Government in Australia to establish a GMP manufacturing facility for RNA immunotherapies. The facility will expedite commercialization of Myeloid’s RNA therapeutics and promote RNA ecosystem growth in NSW.

このレポートを購入する理由?

Get a detailed picture of the Global Nucleic Acid Based Therapeutics Market
Identify segments/areas to invest in over the forecast period in the Global Nucleic Acid Based Therapeutics Market
競争環境を理解する, 市場の主要企業
Excel 形式でのシナリオ全体の分析を容易にするための市場予測
3ヶ月間の戦略コンサルティングとリサーチサポート
シングルユーザーライセンスに提供される印刷認証